NCM·Healthcare·$207M·#502 / 520 in Healthcare
LUCD Lucid Diagnostics Inc.
17CRITICAL
CATEGORY BREAKDOWN
GROWTH13
QUALITY0
STABILITY17
VALUATION0
GOVERNANCE62
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+8.3%
13
> 50% strong
Gross Margin
Revenue retained after direct costs
-41.7%
0
> 50% strong
Cash Runway
Months of cash at current burn rate
9 months
25
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
236.1%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
43.9x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-1047
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
25.8%
94
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+123.6%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE LUCD WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when LUCD's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.